Skip to main content

Table 3 Longitudinal mixed linear models of CSF immune marker change by A/T/N group with stable A-/T-N-overtime as the reference group

From: Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease

CSF markers

Stable A−/T−/N− baseline (intercept)

Stable A−/T−/N− annual change

Stable A+/T−/N− baseline

Stable A+/T−/N− annual change

Stable A+/T+ or N+ baseline

Stable A+/T+ or N+ annual change

Stable A−/T+ or N+ baseline

Stable A−/T+ or N+ annual change

 

b (95% CI)

b (95% CI) [p/p.adj]

b (95% CI) [p/p.adj]

b (95% CI) [p/p.adj]

b (95% CI) [p/p.adj]

b (95% CI) [p/p.adj]

b (95% CI) [p/p.adj]

b (95% CI) [p/p.adj]

sTREM2

− 0.33 (− 0.53; − 0.13)

− 0.01 (− 0.02; 0.39) [0.384/1.0]

− 0.29 (− 0.72; 0.15) [0.199/1.0]

− 0.01 (− 0.07; 0.04) [0.613/1.0]

0.57 (0.29; 0.85) [< 0.001/< 0.001]

0.01 (− 0.01; 0.04) [0.311/1.0]

0.78 (0.41; 1.15) [< 0.001/ < 0.001]

0.01 (− 0.03; 0.05) [0.662/1.0]

YKL-40

− 0.28 (− 0.44; − 0.12)

− 0.03 (− 0.06; − 0.01) [0.039/0.276]

− 0.52 (− 0.88; − 0.16 [< 0.01/< 0.05]

− 0.03 (− 0.10; 0.37) [0.366/1.0]

0.57 (0.34; 0.80) [< 0.001/< 0.001]

− 0.01 (− 0.03; 0.03) [0.886/1.0]

0.75 (0.46; 1.05) [< 0.001/< 0.001]

0.05 (− 0.10; − 0.01) [< 0.05/0.276]

Clusterin

− 0.37 (− 0.57; − 0.18)

0.07 (0.01; 0.13) [0.028/0.198]

− 0.28 (− 0.71; 0.15) [0.196/0.978]

0.24 (0.10; 0.38) [< 0.001/< 0.01]

0.73 (0.43; − 1.03) [< 0.001/< 0.001]

0.03 (− 0.04; 0.09) [0.380/1.0]

0.91 (0.56; 1.25) [< 0.001/< 0.001]

0.03 (− 0.07; 0.13) [0.529/1.0]

fractalkine

− 0.46 (− 0.77; − 0.14)

0.09 (0.03; 0.15) [< 0.01/< 0.05]

− 0.69 (− 1.14; − 0.25) [< 0.01/< 0.05]

0.09 (− 0.02; 0.21) [0.113/0.565]

0.58 (0.29; 0.86) [< 0.001/< 0.001]

0.07 (0.01; 0.12) [< 0.05/.156]

1.05 (0.68; 1.42) [< 0.001/< 0.001]

0.06 (− 0.02; 0.14) [0.156/0.626]

MCP-1

− 0.57 (− 0.80; − 0.35)

0.01 (− 0.06; − 0.07) [0.879/1.0]

0.07 (− 0.38; 0.52) [0.759/1.0]

− 0.03 (0.14; 0.08) [0.589/1.0]

0.47 (0.19; 0.76) [< 0.01/< 0.05]

0.05 (− 0.01; 0.11) [0.100/0.800]

0.54 (0.16; 0.91) [< 0.01/< 0.05]

0.03 (− 0.06; 0.12) [0.473/1.0]

IL-6

− 0.13 (− 0.67; 0.42)

− 0.05 (− 0.12; 0.04) [0.268/1.0]

0.09 (− 0.41; 0.59) [0.727/1.0]

0.07 (− 0.09; 0.23) [0.378/1.0]

0.03 (− 0.27; 0.32) [0.867/1.0]

− 0.06 (− 0.14; 0.02) [0.154/1.0]

0.19 (− 0.23; 0.60) [0.372/1.0]

− 0.16 (− 0.27; − 0.04) [< 0.05/0.095]

IL-10

0.06 (− 0.18; 0.31)

− 0.01 (− 0.05; − 0.04) [0.851/1.0]

− 0.18 (− 0.69; 0.34) [0.502/1.0]

0.07 (− 0.03; 0.16) [0.167/1.0]

0.24 (− 0.08; 0.56) [0.141/1.0]

0.04 (0.00; 0.08) [0.052/.518]

0.18 (− 0.24; 0.60) [0.395/1.0]

0.01 (− 0.06; 0.07) [0.829/1.0]

IL-18

− 0.39 (− 0.84; 0.06)

− 0.02 (− 0.06; 0.03) [0.500/1.0]

− 0.62 (− 1.06; − 0.18) [< 0.01/0.064]

0.06 (− 0.04; 0.15) [0.220/1.0]

0.18 (− 0.10; 0.46) [0.207/1.0]

0.01 (− 0.04; 0.05) [0.831/1.0]

0.36 (− 0.01; 0.73) [0.055/0.492]

− 0.02 (− 0.09; 0.05) [0.527/1.0]

IFN-γ

0.12 (− 0.12; 0.36)

0.03 (− 0.03; 0.09) [0.396/1.0]

− 0.82 (− 1.32; − 0.33) [< 0.01/ < 0.05]

0.11 (− 0.02; 0.24) [0.107/0.967]

− 0.02 (− 0.31; 0.28) [0.898/1.0]

0.04 (− 0.02; 0.10) [0.238/1.0]

0.14 (− 0.27; 0.53) [0.499/1.0]

0.05 (− 0.04; 0.14) [0.298/1.0]

  1. Significant statistical tests (ANOVA or ANCOVA, or between group comparisons after correction for multiple testing) are indicated in bold
  2. A±, CSF positive or negative for amyloid plaques; T±, CSF positive or negative for tau-tangles; N±, CSF positive or negative marker for neurodegeneration; b, unstandardized regression coefficient; SE, standard error; p, p value; p.adj, Bonferroni–Holm adjusted p value. No significant between-group differences in slopes over time (Bonferroni–Holm) as compared with the reference group (stable A−/T−/N−) were found for any biomarker
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094